Clean Chain for Brands - Chemical and Supply Chain Management

| October 14, 2018

article image
CleanChain™, an ADEC Innovation, provides a secure, central solution for managing chemical inventory so your staff have the critical performance insights and improvement plans needed to better run your business – and be rewarded for doing so. Monitoring the progress of your chemical management commitments throughout your extended supply chain is a very manual, labor-intensive process. Rather than spending time managing the data and aggregating information from diverse and distributed sources, ADEC Innovations’ CleanChain provides one system for your chemical data across all suppliers.

Spotlight

Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives throughout more than 100 countries. Valeant’s primary focus is in the areas of dermatology and eye health. Valeant has an established portfolio of durable products and our strategy is to focus the business on core geographies and therapeutic areas that offer high-growth opportunities. Another critical element of our strategy is business development. We have completed numerous transactions over the past few years, including the acquisition of international eye health organization Bausch + Lomb in 2013, to expand our portfolio and our geographic footprint. We will continue to pursue value-added business development opportunities as they arise. Valeant’s strategic markets are primarily in the United States, Can

OTHER ARTICLES

Removal of non-industrial chemicals from the NICNAS Inventory

Article | March 23, 2020

The Australian Government announced its intention to implement reforms to the way in which industrial chemicals are regulated. The reforms are intended to streamline the process of assessing industrial chemicals to reduce the regulatory burden and to make regulatory effort more proportionate to risk. The Industrial Chemicals Act, which was passed by Parliament in February of 2019 and received Royal Assent in March of 2019, creates a new framework for the regulation of imported or manufactured industrial chemicals. The new scheme, referred to as the Australian Industrial Chemicals Introduction Scheme, or AICIS, will replace the current National Industrial Chemicals Notification and Assessment Scheme, referred to as NICNAS.

Read More
CHEMICAL TECHNOLOGY

Closing the loop: Real-time measurement of oil in water for process facilities

Article | March 23, 2020

When an oilfield’s reservoir pressure is depleted during primary recovery, additional oil can be recovered by recycling the produced water and injecting it back into the reservoir. Water management is critical for such water and water-alternating-gas (WAG) floods. In its Permian basin operations, Occidental recovers, recycles, and re-injects large volumes of water for its enhanced oil recovery (EOR) operations. With real-time monitoring of oil in water (OiW) delivering reliable and continuous data, Occidental identified a way to optimize the recovery process and is working with NOV to expand the use of OiW monitoring equipment.

Read More

What is Rate of Reaction and Why is It Important For The Chemical Industry?

Article | March 23, 2020

It would not be an exaggeration to say that the rate of reaction is the true lifeline of the chemical industry in India, and the whole world. A lower rate of reaction would mean, chemical manufacturers can produce products at much faster rates which gives them a great competitive advantage over others. The chemical industry strives to create a faster rate of reactions as it impacts revenue goals.

Read More
CHEMICAL MANAGEMENT

Petrochemicals markets complexity is only going to grow and grow

Article | March 23, 2020

NICE WORK, if you get can get it. A trucking company in Fort Worth, Texas, is offering to pay experienced drivers $14,000 a week – $728,000 a year – as the US struggles with a nationwide shortage of truckers or lorry drivers. This reminds me of perhaps an apocryphal tale, from the height of the last Australian mining boom. Before iron ore prices collapsed in late 2014, there was a story about workers at mining site road junctions who operated manual “Stop and Go” signs. They were said to be earning more than Australian dollar (A$) 200,000 a year. Before you pack in your job as, say, a petrochemicals sales manager and head to Texas or mine sites in Western Australia, there is the risk that when you arrive at the door of your new prospective employer, the bubble might have already burst. This is assuming we are in bubble conditions.The pressure is clearly building in petrochemicals and other commodity markets as prices in some regions remain at record highs or continue to rise. Today’s prices are the results of shortages of commodities supply (for example in petrochemicals, an outcome of the US winter storms), very strong demand and supply chain disruptions.I am beginning to believe that the latter is the biggest reason for commodity price inflation which is feeding through into sharp rises in the cost of finished goods – and a lack of goods availability. It is delivering and manufacturing enough stuff that seems to be at the heart of today’s problems due to shortages of everything from container freight space and semiconductors to wooden pallets, tin cans, metal drums, cardboard – and US truck drivers.

Read More

Spotlight

Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives throughout more than 100 countries. Valeant’s primary focus is in the areas of dermatology and eye health. Valeant has an established portfolio of durable products and our strategy is to focus the business on core geographies and therapeutic areas that offer high-growth opportunities. Another critical element of our strategy is business development. We have completed numerous transactions over the past few years, including the acquisition of international eye health organization Bausch + Lomb in 2013, to expand our portfolio and our geographic footprint. We will continue to pursue value-added business development opportunities as they arise. Valeant’s strategic markets are primarily in the United States, Can

Events